Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Jun 25, 2015
Heptares StaR® Technology and its Impact on GPCR Drug R&D featured in New Report Celebrating UK Bioscience from the UK BioIndustry Association
Jun 17, 2015
Positive Outcome of Phase 1a Study with First-Ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients with Alzheimer's Disease
Events

Jun 28 - Jul 3, 2015
ESMEC
Urbino, Italy
Presenting: Dahlia Weiss

Jul 1-3, 2015
RICT 2015 - Drug Discovery and Selection
Avignon, France
Presenting: John Christopher

© 2012-2015 Heptares Therapeutics